CCR5 and infection: The CCR5 inhibitor TAK-779, which completely blocks Env-mediated cell-cell fusion and infection of CCR5 expressing cells, was included as a control, and it decreased Env-dependent cell-cell fusion by 99±1% and Env-mediated Abl kinase activation by 98% (Figure 2A and S1B).